Trial Profile
A Phase 1b Study of GX-I7 in Combination With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 May 2020
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Efineptakin alfa (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genexine
- 12 May 2020 Status changed from recruiting to completed.
- 17 Nov 2018 New trial record